Kiora Pharmaceuticals (KPRX) Competitors $3.14 +0.03 (+0.80%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. PLUR, ONCY, ELYM, RVPH, ACRV, ALGS, ESLA, ATHE, FBLG, and OSTXShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Pluri (PLUR), Oncolytics Biotech (ONCY), Eliem Therapeutics (ELYM), Reviva Pharmaceuticals (RVPH), Acrivon Therapeutics (ACRV), Aligos Therapeutics (ALGS), Estrella Immunopharma (ESLA), Alterity Therapeutics (ATHE), FibroBiologics (FBLG), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Pluri Oncolytics Biotech Eliem Therapeutics Reviva Pharmaceuticals Acrivon Therapeutics Aligos Therapeutics Estrella Immunopharma Alterity Therapeutics FibroBiologics OS Therapies Pluri (NASDAQ:PLUR) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership. Which has higher earnings and valuation, PLUR or KPRX? Kiora Pharmaceuticals has higher revenue and earnings than Pluri. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.03M33.63-$20.89M-$5.53-0.80Kiora Pharmaceuticals$16M0.60-$12.51M-$2.90-1.08 Do analysts rate PLUR or KPRX? Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 218.98%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is PLUR or KPRX more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Kiora Pharmaceuticals' return on equity of 21.32% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-3,551.49% -2,778.13% -83.61% Kiora Pharmaceuticals N/A 21.32%16.39% Does the MarketBeat Community believe in PLUR or KPRX? Kiora Pharmaceuticals received 18 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformPluriN/AN/AKiora PharmaceuticalsOutperform Votes1875.00% Underperform Votes625.00% Does the media prefer PLUR or KPRX? In the previous week, Pluri had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Pluri and 0 mentions for Kiora Pharmaceuticals. Pluri's average media sentiment score of 0.42 beat Kiora Pharmaceuticals' score of 0.00 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Neutral Kiora Pharmaceuticals Neutral Which has more risk & volatility, PLUR or KPRX? Pluri has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.67, meaning that its stock price is 167% less volatile than the S&P 500. Do insiders & institutionals have more ownership in PLUR or KPRX? 16.6% of Pluri shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 10.2% of Pluri shares are held by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryKiora Pharmaceuticals beats Pluri on 12 of the 18 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.54M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.089.1226.8519.75Price / Sales0.60256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.446.436.764.50Net Income-$12.51M$144.21M$3.23B$248.32M7 Day Performance0.16%2.25%1.71%0.48%1 Month Performance3.81%4.39%11.16%13.08%1 Year Performance-35.49%-2.71%17.17%7.36% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals2.5797 of 5 stars$3.14+0.8%$10.00+219.0%-38.1%$9.54M$16M-1.0810PLURPluri0.4083 of 5 stars$4.95-5.0%N/A-25.8%$38.47M$678,000.00-0.88150Gap UpONCYOncolytics Biotech1.7277 of 5 stars$0.44-4.9%$4.33+874.7%-62.1%$38.42MN/A-1.6530Analyst ForecastELYMEliem TherapeuticsN/A$1.29+7.5%N/A-84.2%$38.38MN/A-2.439RVPHReviva Pharmaceuticals3.4329 of 5 stars$0.89+8.5%$10.00+1,023.6%-24.1%$38.33MN/A-0.805News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionACRVAcrivon Therapeutics3.1856 of 5 stars$1.18+2.6%$17.71+1,401.2%-86.0%$37.00MN/A-0.4458Analyst RevisionGap UpHigh Trading VolumeALGSAligos Therapeutics3.4175 of 5 stars$5.89+0.9%$70.00+1,088.5%-64.7%$36.01M$3.27M-0.4490ESLAEstrella Immunopharma1.4986 of 5 stars$0.99+2.7%$16.00+1,524.4%+2.0%$35.62MN/A-3.79N/AGap UpATHEAlterity Therapeutics1.9629 of 5 stars$4.05+1.5%$12.00+196.3%+104.5%$35.38MN/A0.0010Gap UpFBLGFibroBiologics1.5708 of 5 stars$0.91-2.5%$13.00+1,327.2%-91.7%$34.85MN/A-4.3410OSTXOS Therapies2.0642 of 5 stars$1.59-3.0%$18.00+1,032.1%N/A$34.45MN/A-1.85N/AGap Up Related Companies and Tools Related Companies Pluri Competitors Oncolytics Biotech Competitors Eliem Therapeutics Competitors Reviva Pharmaceuticals Competitors Acrivon Therapeutics Competitors Aligos Therapeutics Competitors Estrella Immunopharma Competitors Alterity Therapeutics Competitors FibroBiologics Competitors OS Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KPRX Stock Free KPRX Stock Alerts